BusinessTPP Healthcare to Host China Partnering Forum at Leading MedTech ConferenceBy Nasdaq OMXOct 5, 2016, 1:05 PM UTC
BusinessAchillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCVBy Nasdaq OMXSep 23, 2016, 3:50 PM UTC
BusinessHemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing StandardsBy Nasdaq OMXSep 19, 2016, 12:30 PM UTC
BusinessThe Respiratory Disorders Market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%: ResearchMozBy Nasdaq OMXSep 16, 2016, 1:18 PM UTC
BusinessFrontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes: ResearchMozBy Nasdaq OMXSep 16, 2016, 11:05 AM UTC
BusinessThe Respiratory Disorders Market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%: ResearchMozBy Nasdaq OMXSep 15, 2016, 12:34 PM UTC
BusinessAchillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCVBy Nasdaq OMXSep 9, 2016, 10:15 AM UTC
BusinessHemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment ConferenceBy Nasdaq OMXSep 6, 2016, 12:30 PM UTC
